SOURCE: Alliance for Regenerative Medicine

Alliance for Regenerative Medicine

August 06, 2015 08:00 ET

The Alliance for Regenerative Medicine Announces Presenting Companies at 2015 Stem Cell Meeting on the Mesa

More Than 60 Leading Companies Across the Sector Will Present at This Year's Event, Collectively Conducting 125+ Clinical Trials Developing 165+ Unique Therapeutic Products

WASHINGTON, DC--(Marketwired - Aug 6, 2015) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the interests of the advanced therapies and regenerative medicine community, today announced the initial slate of companies selected to present at its upcoming Stem Cell Meeting on the Mesa (SCMOM) Partnering Forum.

The meeting will feature presentations from more than 60 leading companies in the fields of cell therapy, gene and gene-modified cell therapy and tissue engineering. The Partnering Forum will take place October 7 and 8, 2015 at the Estancia Hotel in La Jolla, California as part of the full SCMOM conference, which also features a Scientific Symposium on October 9, 2015.

Collectively, the initial slate of presenting companies are currently conducting 125+ clinical trials with an additional 130 studies in the pre-clinical or research phase and 15+ products on the market. Altogether, these companies are developing 165+ unique products across a range of possible therapeutic applications.

Initial slate of presenting companies:

Abeona Therapeutics, Argos Therapeutics, Asterias Biotherapeutics, Avalanche Biotech, BioLife Solutions, bluebird bio, BrainStorm Cell Therapeutics, Caladrius Biosciences, Capricor Therapeutics, Cellectis, Cell Therapy Ltd., Cellular Dynamics International, Celyad, Cesca Therapeutics, Cyfuse, DiscGenics, Editas Medicine, Fate Therapeutics, Fibrocell Science, GenVec, HemoStemix, Histogenics, Inovio Pharmaceuticals, InVivo Therapeutics, jCyte, Juventas Therapeutics, Kiadis Pharma, MaxCyte, MEDIPOST America, Mesoblast Ltd., MiMedx, MolMed, Opexa Therapeutics, Organovo, Orthocell, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, Regenerative Patch Technologies, REGENXBIO, ReNeuron, RepliCel, Sangamo BioSciences, StemBioSys, StemCells, Inc., TaiwanBio, Terumo BCT, TiGenix, TissueGene, uniQure, Vericel, ViaCyte, Voyager Therapeutics

Additions to the list above, as well as a detailed agenda and company presentation times, will be released closer to the event date.

The Partnering Forum at SCMOM is the largest annual partnering meeting organized specifically for the regenerative medicine and advanced therapies community. Presenting companies will be available for one-on-one partnering opportunities and strategic dealmaking using a state-of-the-art partnering software.

Since its inception in 2011, attendance at SCMOM has more than doubled, with the number of scheduled one-on-one partnering meetings more than tripling. Nearly 800 key decision makers across the sector are expected to attend this year's event.

Registration is open, with discounted early-bird rates available through August 28. Registration is complimentary for investors and credentialed members of the media. For members of the media interested in attending, please contact Lyndsey Scull at lscull@alliancerm.org.

Complimentary attendance to the October 9 Scientific Symposium is available for the first 50 students who register using discount code STUDENT15. A current student ID will be required onsite at the meeting upon checking in.

To learn more and to register, please visit www.stemcellmeetingonthemesa.com.

About the Stem Cell Meeting on the Mesa

The Stem Cell Meeting on the Mesa is hosted by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine. This three-day conference brings together senior executives and top decision makers in the regenerative medicine and advanced therapies industry within the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first and only event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract nearly 800 attendees, fostering key partnerships through more than 500 one-on-one meetings while highlighting the significant clinical and commercial progress in the field over the past year.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 220 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Contact Information